Ventyx Biosciences (NASDAQ:VTYX) Insider John Nuss Sells 12,675 Shares

Ventyx Biosciences, Inc. (NASDAQ:VTYX) insider John Nuss sold 12,675 shares of the stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $97,851.00. Following the completion of the transaction, the insider owned 489,481 shares of the company’s stock, valued at approximately $3,778,793.32. The trade was a 2.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Ventyx Biosciences Price Performance

NASDAQ VTYX traded up $1.00 during trading hours on Friday, reaching $8.74. 2,836,325 shares of the company’s stock traded hands, compared to its average volume of 2,101,134. Ventyx Biosciences, Inc. has a 52-week low of $0.78 and a 52-week high of $10.55. The firm has a 50-day simple moving average of $7.79 and a 200 day simple moving average of $4.44. The firm has a market cap of $623.69 million, a PE ratio of -5.83 and a beta of 1.22.

Ventyx Biosciences (NASDAQ:VTYX) last announced its earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.13. Sell-side analysts forecast that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on VTYX. Weiss Ratings reissued a “sell (d-)” rating on shares of Ventyx Biosciences in a report on Wednesday, October 8th. Wells Fargo & Company lifted their price target on Ventyx Biosciences from $11.00 to $14.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Oppenheimer increased their price objective on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a research report on Monday, October 27th. HC Wainwright raised shares of Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 target price for the company in a report on Wednesday, November 5th. Finally, Canaccord Genuity Group upped their target price on shares of Ventyx Biosciences from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $15.50.

Hedge Funds Weigh In On Ventyx Biosciences

Several institutional investors have recently made changes to their positions in the business. Nuveen LLC bought a new stake in Ventyx Biosciences during the first quarter valued at approximately $194,000. Walleye Capital LLC boosted its stake in shares of Ventyx Biosciences by 5.5% during the 1st quarter. Walleye Capital LLC now owns 504,245 shares of the company’s stock worth $580,000 after acquiring an additional 26,457 shares during the last quarter. Ieq Capital LLC purchased a new position in shares of Ventyx Biosciences during the 1st quarter worth $223,000. Redmile Group LLC grew its position in shares of Ventyx Biosciences by 1,164.1% during the 1st quarter. Redmile Group LLC now owns 1,569,793 shares of the company’s stock valued at $1,805,000 after acquiring an additional 1,445,615 shares during the period. Finally, ADAR1 Capital Management LLC increased its stake in shares of Ventyx Biosciences by 126.1% in the 1st quarter. ADAR1 Capital Management LLC now owns 281,600 shares of the company’s stock worth $324,000 after purchasing an additional 157,070 shares in the last quarter. Institutional investors own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.